AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
June 08, 2018-- In the MURANO Phase 3 clinical trial, the VENCLEXTA® (venetoclax tablets) plus rituximab combination showed a significant improvement in progression-free survival (PFS) for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients, reducing the risk of disease progression or death by 81 percent when compared to a standard of care chemoimmunotherapy regimen, bendamustine plus rituximab (1)
-
June 04, 2018- Hidradenitis suppurativa (HS) is a painful, debilitating, chronic inflammatory skin disease estimated to affect 1 - 4 percent of the world's population(1),(2)
-
May 01, 2018- Application supported by four pivotal Phase 3 trials evaluating more than 2,000 patients with moderate to severe plaque psoriasis (1-3)
-
March 28, 2018-- Scholarship awards $3,000 to 40 exceptional students with cystic fibrosis (CF) for academic excellence, creativity and community service
Our history
 |
Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Ratings and recognition
 |
We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
